###begin article-title 0
An LRP5 Receptor with Internal Deletion in Hyperparathyroid Tumors with Implications for Deregulated WNT/beta-Catenin Signaling
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 607 613 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
Hyperparathyroidism (HPT) is a common endocrine disorder with incompletely understood etiology, characterized by enlarged hyperactive parathyroid glands and increased serum concentrations of parathyroid hormone and ionized calcium. We have recently reported activation of the Wnt signaling pathway by accumulation of beta-catenin in all analyzed parathyroid tumors from patients with primary HPT (pHPT) and in hyperplastic parathyroid glands from patients with uremia secondary to HPT (sHPT). Mechanisms that may account for this activation have not been identified, except for a few cases of beta-catenin (CTNNB1) stabilizing mutation in pHPT tumors.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 528 531 522 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 662 667 <span type="species:ncbi:10090">mouse</span>
Reverse transcription PCR and Western blot analysis showed expression of an aberrantly spliced internally truncated WNT coreceptor low-density lipoprotein receptor-related protein 5 (LRP5) in 32 out of 37 pHPT tumors (86%) and 20 out of 20 sHPT tumors (100%). Stabilizing mutation of CTNNB1 and expression of the internally truncated LRP5 receptor was mutually exclusive. Expression of the truncated LRP5 receptor was required to maintain the nonphosphorylated active beta-catenin level, transcription activity of beta-catenin, MYC expression, parathyroid cell growth in vitro, and parathyroid tumor growth in a xenograft severe combined immunodeficiency (SCID) mouse model. WNT3 ligand and the internally truncated LRP5 receptor strongly activated transcription, and the internally truncated LRP5 receptor was insensitive to inhibition by DKK1.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
The internally truncated LRP5 receptor is strongly implicated in deregulated activation of the WNT/beta-catenin signaling pathway in hyperparathyroid tumors, and presents a potential target for therapeutic intervention.
###end p 6
###begin p 7
Gunnar Westin and colleagues report the expression of an aberrantly spliced LRP5 receptor in primary and spontaneous parathyroid tumors and implicate it in the deregulated activation of the Wnt/beta-catenin signaling pathway.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 28 32 <span type="species:ncbi:4530">rice</span>
###xml 828 836 <span type="species:ncbi:9606">patients</span>
The parathyroid glands-four rice-sized glands in the neck-maintain a normal calcium balance in the body, to maintain strong bones and essential cellular functions. The glands release parathyroid hormone as a response to a decrease in blood calcium level. By stimulating calcium release from bone and its absorption in the gut, parathyroid hormone restores the blood calcium level. However, 100,000 new individuals in the US develop hyperparathyroidism (HPT) annually, characterized by enlarged, overactive parathyroid glands and high blood levels of calcium. Primary HPT (pHPT) is usually caused by a benign tumor (a non-life-threatening growth) in one of the parathyroid glands. Secondary HPT (sHPT) occurs in response to calcium regulatory disturbances, linked to vitamin D deficiency, and more or less invariably develops in patients with uremic kidney disease.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 361 369 <span type="species:ncbi:9606">patients</span>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
HPT is usually treated by surgical removal of the enlarged parathyroid glands, which is done with great efficiency. However, ideally, doctors would like to know what drives the overgrowth of the parathyroid glands to be able to develop drugs for treatment or disease prophylaxis. Researchers recently reported that the cells in enlarged parathyroid glands from patients with HPT contain high amounts of beta-catenin. This protein is part of the Wnt signaling pathway, which has been found to be disrupted in many tumor entities in other organs. In the absence of Wnt proteins, a group of proteins called the beta-catenin destruction complex marks beta-catenin so that it is rapidly destroyed. When Wnt proteins bind to a cell-surface receptor called Frizzled and a coreceptor called LRP5, the destruction complex is inhibited and beta-catenin accumulates. This accumulation induces the production of other proteins (in particular, c-Myc) that stimulate cell growth and division. The accumulation of beta-catenin in the enlarged parathyroid glands of patients with HPT could, therefore, significantly contribute to the overgrowth of their glands-but what causes beta-catenin accumulation? In this study, the researchers have investigated this question to try to identify a target for drugs to treat HPT.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
The researchers looked for genetic changes (mutations) in beta-catenin that stabilize the protein and measured the expression of LRP5 in abnormal parathyroid gland tissue from 37 patients with pHPT and 20 with uremia and sHPT. All the samples contained high levels of beta-catenin, but only four contained a beta-catenin-stabilizing mutation. All the sHPT samples and 32 pHPT samples (but none of the samples containing the beta-catenin stabilizing mutation) expressed a mutated LRP5, with the central region deleted. To investigate the functional consequences of this internally deleted LRP5 protein, the researchers used a technique called RNA interference to block its expression in a human parathyroid tumor cell line. They found that expression of the mutated, short LRP5 is required for accumulation of beta-catenin, expression of c-Myc, and continued growth of the cell line in test tubes and in animals.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
The accumulation of beta-catenin in all the enlarged parathyroid glands examined so far strongly implicates abnormal Wnt/beta-catenin signaling in the development of pHPT and sHPT. These new findings identify which part of the signaling pathway is altered. The expression data and functional data together suggest that an internally deleted LRP5 coreceptor is often responsible for the accumulation of beta-catenin. The functional data also show that expression of shortened LRP5 is necessary for the abnormal growth of parathyroid tumor cells. Exactly how the internally deleted coreceptor activates beta-catenin signaling in parathyroid gland cells, or why a shorter-than-normal LRP5 is made, are not yet known. However, because these findings indicate that internally deleted LRP5 has a fundamental role in activating Wnt signaling in HPT, drugs that inactivate this aberrant protein but leave the normal protein unscathed might provide a nonsurgical treatment for this common hormone disorder.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
edlinePlus has encyclopedia pages on , , and  (in English and Spanish)
###end p 19
###begin p 20
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 168 174 <span type="species:ncbi:9606">people</span>
Information is available for patients from the US National Institute of Diabetes and Digestive and Kidney Diseases on , which includes links to organizations that help people with hyperparathyroidism
###end p 20
###begin p 21
Wikipedia maintains pages on  and on  (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages)
###end p 21
###begin title 22
Introduction
###end title 22
###begin p 23
###xml 330 331 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b001">1</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b004">4</xref>
###xml 721 722 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 725 728 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 901 902 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b006">6</xref>
###xml 903 904 897 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b007">7</xref>
###xml 988 989 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 1087 1090 1078 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1106 1111 1097 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1192 1193 1183 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 1269 1270 1260 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b002">2</xref>
###xml 1378 1379 1369 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b009">9</xref>
###xml 1470 1475 1461 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1564 1567 1555 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTH</italic>
###xml 1579 1581 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b010">10</xref>
###xml 1711 1712 1699 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 1760 1765 1748 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 1801 1803 1786 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b011">11</xref>
###xml 1844 1850 1829 1835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 2059 2060 2044 2045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 1157 1162 <span type="species:ncbi:9606">human</span>
###xml 1334 1349 <span type="species:ncbi:10090">transgenic mice</span>
Primary hyperparathyroidism (pHPT) is characterized by hypersecretion of parathyroid hormone and generally also hypercalcemia, due to one or several parathyroid tumors (adenoma). Secondary hyperparathyroidism (sHPT) develops in patients with uremia because of phosphate retention, hypocalcemia, and reduced 1,25-dihydroxyvitamin D3 levels, causing parathyroid hyperplasia and eventually development of parathyroid tumors and hypercalcemia [1-4]. Parathyroidectomy is the only considered therapy for most patients. We recently reported aberrant beta-catenin (CTNNB1) accumulation in all analyzed parathyroid tumors from patients with pHPT and in hyperplastic parathyroid glands from patients with uremia secondary to HPT [5]. MYC, a direct target of the Wnt/beta-catenin signaling pathway in colorectal cancer cells and established as the critical mediator of the early stages of intestinal neoplasia [6,7], was found to be overexpressed at the protein level in 79% of parathyroid tumors [5]. Maintained activity of endogenous beta-catenin was found to be necessary for the expression of MYC and cyclin D1 (CCND1), as well as growth and survival of a unique human parathyroid tumor cell line [8]. Overexpression of cyclin D1 has been reported in 20%-40% of pHPT tumors [2], and overexpression of cyclin D1 in the parathyroid glands of transgenic mice caused development of pHPT [9]. In a small fraction of parathyroid adenomas, overexpression is due to activation of the CCND1 gene by pericentromeric inversions of Chromosome 11, involving the parathyroid hormone (PTH) promoter [10]. Augmented cyclin D1 expression in some parathyroid adenomas could also be a consequence of aberrant beta-catenin accumulation [5], although it remains to be determined whether CCND1 constitutes a beta-catenin target [11] in parathyroid cells. We also reported CTNNB1 stabilizing mutations in a few cases (3 out of 20) of pHPT tumors, while no mutation was found in uremic secondary HPT tumors, and inactivating truncations of adenomatosis polyposis coli (APC) were not seen [5]. Mutation or deregulated expression of other Wnt-signaling components leading to beta-catenin accumulation was therefore anticipated.
###end p 23
###begin p 24
###xml 496 498 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b012">12</xref>
###xml 499 501 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b015">15</xref>
###xml 734 736 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b016">16</xref>
###xml 737 739 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b019">19</xref>
###xml 876 878 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b020">20</xref>
###xml 1286 1292 1259 1265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 1322 1325 1295 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 1428 1430 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b013">13</xref>
###xml 1431 1433 1404 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b014">14</xref>
###xml 1541 1543 1514 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b020">20</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
Dysregulated Wnt signaling with accumulation of beta-catenin in the cytoplasm/nucleus plays an important role in a variety of human cancers. The stability of beta-catenin is regulated by Wnt ligands through a "destruction complex" consisting of APC/Axin/GSK-3beta/Ck1/Dvl and other factors. In the absence of Wnt ligand, free cytoplasmic beta-catenin is rapidly degraded by the proteasome after phosphorylation of its amino terminus at residues serine 33, serine 37, threonine 41, and serine 45 [12-15]. Wnt ligands bind to cell-surface Frizzled receptors and LRP5/6 coreceptors and result in changes in phosphorylation of several intracellular signaling components with the subsequent accumulation of nonphosphorylated beta-catenin [16-19]. According to a current model, the destruction complex is inactivated through recruitment of Axin to the intracellular domain of LRP5 [20]. beta-catenin binds the LEF/TCF family of transcription factors to positively or negatively regulate transcription of target genes. Many mutant proteins of the Wnt signaling pathway, such as beta-catenin, APC, Axin, and beta-transducin repeat-containing protein (beta-Trcp), are associated with specific forms of cancer. For instance, aberrant accumulation of beta-catenin through stabilizing mutations in CTNNB1 or inactivating mutations in APC is strongly implicated in the cause of approximately 10% and 80% of colorectal cancers, respectively [13,14]. A mutant of LRP5 lacking the extracellular domain was demonstrated to be constitutively active in vitro [20]. In this study, we aimed at investigating the potential role of LRP5 in parathyroid tumorigenesis.
###end p 24
###begin title 25
Methods
###end title 25
###begin title 26
Tissue Specimens
###end title 26
###begin p 27
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 55 56 55 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 416 417 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 447 448 444 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
Parathyroid adenomas (n = 37) and hyperplastic glands (n = 20) from patients with pHPT and sHPT, respectively, were acquired from patients diagnosed and operated on in the clinical routine. Each patient contributed with one tumor. All 57 tumors displayed aberrant accumulation of beta-catenin (unpublished data), of which 14 parathyroid adenomas and all 20 hyperplastic parathyroid glands were described previously [5]. Normal parathyroid tissue (n = 6) was obtained from glands inadvertently removed in conjunction with thyroid surgery where autotransplantation was not required or as normal parathyroid gland biopsies in patients subjected to parathyroidectomy. All tissues were intraoperatively snap-frozen, and cryosections were used in the analyses. Written informed consent and approval of local ethics committee was obtained.
###end p 27
###begin title 28
Detection of Normal and Internally Truncated LRP5 Transcripts by PCR and DNA Sequencing
###end title 28
###begin p 29
###xml 1089 1090 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Total RNA was extracted with TriZol Reagent (Gibco BRL, Life Technologies) according to the manufacturer's instructions and the RNA was subsequently treated with RQ1 DNase I (Promega) and proteinase K. Alternatively, DNA-free RNA was prepared using the Nucleospin RNA II kit (Macherey-Nagel). Successful DNase treatments were established by PCR analysis of all RNA preparations. Reverse transcription of total DNA-free RNA was performed with random hexamer primers using the First-Strand cDNA Synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. cDNA was amplified by primary or nested PCR using mRNA-specific primers spanning positions 1992-2932 of LRP5 (GenBank accession number AF064548; ). A total of 1%-2% of the primary PCR product was used for nested PCR. Primers used were the following: forward primer, 5'-CTTCACCAGCAGAGCCGCCATCCACAG-3'; nested forward, 5'-GGATCTCCCTCGAGACCAATAACAACG-3'; and reverse, 5'-CCGGGATCATCC GACTGATG-3'. The PCR amplifications were performed with cDNA, 25 pmol of each primer, 0.2 mM dNTPs, 1x PCR buffer, 1.5 mM MgCl2, and 0.25 U Platinum Taq DNA polymerase (Invitrogen). The PCR conditions were: denaturation at 95 degreesC for 60 s, followed by 40 cycles of denaturation for 20 s, annealing at 58 degreesC for 20 s and extension at 72 degreesC for 90 s, and a final extension at 72 degreesC for 7 min. An annealing temperature of 61 degreesC and 40 cycles were used for nested amplification. Two LRP5wt and six randomly chosen truncated LRP5 cDNA fragments from parathyroid tumors, as well as from sHPT-1 cells, were cloned into pCRII-TOPO (Invitrogen), and sequenced on ABI 373A using the ABI Prism Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems). All fragments encoded an open reading frame, and the seven truncated fragments contained the same in-frame deletion (Delta666-809). Normal tissue cDNA or RNA were purchased from BD Biosciences Clontech and Ambion.
###end p 29
###begin title 30
Cell Growth Determination and Flow Cytometry
###end title 30
###begin p 31
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 69 75 <span type="species:ncbi:9913">bovine</span>
Cells (2 x 105) were distributed onto 35-mm dishes in DMEM/10% fetal bovine serum and subsequently harvested at the indicated time points. The number of viable cells were determined by using the NucleoCounter (ChemoMetec). Cells were collected at 84 h after siRNA transfection and incubated with FITC-labeled annexin V to assess phosphatidylserine externalization as a marker for apoptosis.
###end p 31
###begin p 32
Propidium iodide was added to distinguish tumor cells that had lost membrane integrity. Cells were analyzed by flow cytometry on a Becton Dickinson FACS Calibur flow cytometer (BD Biosciences).
###end p 32
###begin title 33
RT-PCR Analyses
###end title 33
###begin p 34
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b021">21</xref>
cDNA was prepared as described above. The following mRNA-specific PCR primers and labeled probes (5'FAM-sequence-3'TAMRA) were used for quantitative real-time RT-PCR analysis. For LRP5wt: forward: 5'-CCTGAAGACCATCAGCCGCG-3'; reverse, 5'-CCCGCTCCTGACCCAGCATG-3'; and probe, 5'-TCCCACCAAGGGCTACATCTACTG-3'. For LRP5tot: forward, 5'-ATCGACTGTATCCCCGGGGC-3'; reverse, 5'-CACCACGCGCTGGCACACAA-3'; and probe, 5'-CGGACTGTGACGCCATCTGCCTGC-3'. For MYC: forward, 5'-AAGACTCCAGCGCCTTCTCTCCGT-3'; reverse, 5'-TGGGCTGTGAGGAGGTTTGCTGTG-3'; and probe, 5'-AGCGACTCTGAGGAGGAACAAGAA-3'. For 28S rRNA, the Ribosomal RNA Control Reagents (VIC probe) was used (Applied Biosystems). PCR reactions were performed on ABI PRISM 7700 Sequence Detection System or MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad) using the TaqMan PCR core Reagent Kit (Applied Biosystems). Each cDNA sample was analyzed in triplicate. Standard curves for the expressed genes were established by amplifying a purified PCR fragment covering the sites for probes and primers. Messenger RNA-specific PCR primers for WNT1 were as described [21]. Primers for WNT3 were as follows: forward, 5'-GGCTGTGACTCGCATCATAA-3'; reverse, 5'-CAGCAGGTCTTCACCTCACA-3'.
###end p 34
###begin title 35
Transfection Experiments, Western Blotting, and Immunoprecipitation
###end title 35
###begin p 36
###xml 32 33 32 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 828 829 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 1319 1321 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b022">22</xref>
###xml 1389 1391 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b023">23</xref>
###xml 2203 2205 2185 2187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b024">24</xref>
###xml 2269 2271 2248 2250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b025">25</xref>
###xml 1361 1364 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 2273 2278 <span type="species:ncbi:10090">mouse</span>
###xml 2343 2347 <span type="species:ncbi:9925">goat</span>
###xml 2432 2436 <span type="species:ncbi:9925">goat</span>
###xml 2480 2486 <span type="species:ncbi:9986">rabbit</span>
###xml 3089 3093 <span type="species:ncbi:9925">goat</span>
sHPT-1 parathyroid tumor cells [8] were transfected with siRNA at least in triplicates at 2 x 105 cells/35-mm dish with jetSI-ENDO according to the manufacturer's recommendations (Poly-Plus-Transfection SAS). The following siRNAs were used: control nonsilencing siRNA (Qiagen Operon), siLRP5Delta666-809; 5'-TAACAACGACCUCACCAUUdTdT-3' and 5'-AAUGGUGAGGUCGUUGUUAdTdT-3' (synthesized by Thermo Electron, Ulm, Germany), siLRP5wt; 5'-CAACCACAUCUACUGGACAdTdT-3' and 5'-UUCCAGUAGAUGUGGUUGdTdT-3' (Thermo Electron), siLRP5tot; stealth 5'-CCUGCAUGGACUGAGGAACGUCAAA-3' and stealth 5'-UUUGACGUUCCUCAGUCCAUGCAGG-3', control siLRP5tot; stealth 5'-CCUGGUAGUCAAGGAUGCACCGAAA-3' and stealth 5'-UUUCGGUGCAUCCUUGACUACCAGG-3' (Invitrogen). A very high transfection efficiency (virtually all cells) was obtained for sHPT-1 cells by this protocol [8]. HeLa cells were transfected in the same manner, with a transfection efficiency of approximately 90% (data not shown). Conditioned medium was produced in HEK293T cells transiently transfected for 24 h by pCIN4/Wnt1 (kind gift from Dr. R. Kemler), pLNC Wnt-3HA (kind gift from Dr. J. Kitajewski), PON-Wnt-3a (kind gift from Dr. B. Williams), or pCS2/Dkk1 (kind gift from Dr. S. Y. Sokol) using Fugene 6 (Roche Diagnostics). sHPT-1 cells were transfected with the FOPFLASH or TOPFLASH TCF [22] luciferase reporter (Upstate) and the CMV-LacZ reference plasmid [23] for 24 h using jetPEI (Poly-Plus-Transfection SAS). In some experiments, TOPFLASH was transfected; transfection of siRNA to the same culture was done after 24 h and cells were harvested 96 h later. Luciferase and beta-galactosidase activities were determined luminometrically, and luciferase activity was normalized for differences in beta-galactosidase activity. Expression plasmid LRP5Delta666-809 was constructed by replacing the XhoI/KpnI fragment of pcDNA3.1/LRP5 and pcDNA3.1/V5-His/LRP5 (expressing tagged LRP5) with a XhoI/KpnI-digested PCR fragment harboring the deletion Delta666-809. Western blotting analyses were done on extracts prepared in Cytobuster Protein Extract Reagent (Novagen) supplemented with Complete protease inhibitor cocktail (Roche Diagnostics) or on a cytosolic protein extract [24]. Anti-V5-HRP antibody (Invitrogen), anti-active-beta-catenin [25] mouse monoclonal antibody (Upstate; catalog number 05-665), anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnology; catalog number sc-21390), anti-actin goat polyclonal antibody, and anti-beta-tubulin rabbit polyclonal antibody (Santa Cruz Biotechnology) were used. For tumor specimens, protein extracts for Western blotting were prepared from 10 consecutive frozen tissue sections (6 mum) in Cytobuster Protein Extract Reagent (Novagen) supplemented with Complete protease inhibitor cocktail (Roche Diagnostics). For immunoprecipitations, cells were resuspended in 300 mul buffer (50 mM Tris [pH 8.0], 150 mM Nacl, 0.5% NP-40, 50 mM NaF, and 1 mM EDTA, supplemented with Complete protease inhibitor cocktail), kept on ice for 20 min, and centrifuged for 20 s at 14,000 rpm. After addition of 20 mul anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnology; catalog number sc-21390), the lysate was incubated overnight at 4 degreesC with gentle agitation. A total of 50 mul Protein G PLUS-Agarose (Santa Cruz Biotechnology; catalog number sc-2002) was then added to the lysate and further incubated for 6 h. After centrifugation, the sample was boiled in 40 mul Laemmli sample buffer for 10 min and 10-20 mul was subjected to Western blotting analysis.
###end p 36
###begin title 37
ChIP Assay
###end title 37
###begin p 38
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b026">26</xref>
###xml 218 220 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b025">25</xref>
###xml 268 271 265 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 319 321 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b022">22</xref>
###xml 191 196 <span type="species:ncbi:10090">mouse</span>
Chromatin immunoprecipitation (ChIP) of transfected cells was performed using a protocol from Upstate, but with immunoprecipitation conditions as described [26]. The anti-active-beta-catenin mouse monoclonal antibody [25] was used (Upstate; catalog number 05-665) and MYC promoter DNA, containing TCF-4 binding site 2 [22], was PCR amplified in the linear range by the following primers: forward, 5'-ACGTGGCAATGCGTTGCTGGG-3'; and reverse, 5'-ACACAGAGAACGCACTGCGCG-3'.
###end p 38
###begin title 39
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Xenograft Model
###end title 39
###begin p 40
###xml 379 380 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 721 723 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b027">27</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Female Fox Chase severe combined immunodeficiency (SCID) mice (2- to 3-wk-old) were used (Taconic). The mice were anesthetized with isoflurane (Forene; Abbott ) during the manipulations. One flank or both flanks of each animal were injected subcutaneously (total 200 mul) with sHPT-1 cells together (1:1) with BD Matrigel Matrix (BD Biosciences Clontech) after transfection of 106 cells for 24 h. The animals were monitored every day and humanely killed after 8-9 wk. The animal experiments were approved by the Uppsala University board of animal experimentation and were performed according to the United Kingdom Coordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia [27].
###end p 40
###begin title 41
Statistical Analysis
###end title 41
###begin p 42
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 132 133 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Unpaired t test was used for all statistical analyses. Values are presented as arithmetrical mean +/- standard error of the mean. A p-value below 0.05 was considered significant.
###end p 42
###begin title 43
Results
###end title 43
###begin title 44
An Internally Truncated LRP5 Receptor Is Expressed in Parathyroid Tumors
###end title 44
###begin p 45
###xml 187 195 183 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 235 236 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 323 324 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 708 709 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 828 836 804 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 1068 1076 1040 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 1086 1092 1058 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 1119 1120 1091 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 1307 1315 1279 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g002">Figure 2</xref>
###xml 1372 1380 1344 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 1536 1542 1500 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 1026 1031 <span type="species:ncbi:9606">human</span>
A shorter LRP5 transcript (LRP5Delta666-809) was detected in 32 out of 37 pHPT tumors (86%) and 20 out of 20 sHPT tumors (100%) by using RT-PCR primers located in exons 9 and 13 of LRP5 (Figure 1A). Of the analyzed parathyroid tumors (n = 57) which all displayed aberrant cytoplasmic/nuclear accumulation of beta-catenin ([5] and unpublished data), four pHPT tumors without the LRP5Delta666-809 transcript harbored the stabilizing mutation of the beta-catenin exon 3 (S37A), and one pHPT tumor had neither. Three out of the four tumors with beta-catenin mutation were reported previously, and the one tumor without beta-catenin mutation or the LRP5Delta666-809 transcript displayed wild-type APC expression [5]. Six normal parathyroid tissues and a panel of 17 normal tissues expressed only the normal LRP5 (LRP5wt) transcript (Figure 1B). Accordingly, a smaller LRP5 protein was detected by immunoprecipitation followed by Western blot analysis of the parathyroid tumors expressing the LRP5Delta666-809 transcript and in the human parathyroid tumor cell line sHPT-1 (Figure 1C), where CTNNB1 is not mutated in exon 3 [8]. The expression level of the smaller form of LRP5 varied in relation to LRP5wt among the analyzed tumors. In the sHPT-1 cell line, it was expressed at a higher relative level (see also Figure 2C). Only the LRP5wt receptor was detected in HeLa cells (Figure 1C), which did not express the truncated LRP5Delta666-809 transcript (unpublished data). No apparent relationships between expression of LRP5Delta666-809 or CTNNB1 stabilizing mutation and clinical characteristics, such as glandular weight or serum levels of parathyroid hormone or calcium, were found.
###end p 45
###begin title 46
An Internally Truncated LRP5 Receptor Is Expressed in Parathyroid Tumors
###end title 46
###begin p 47
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
(A) RT-PCR analysis of RNA from pHPT tumors (n = 20) and sHPT tumors (n = 20) using primers located in exons 9 and 13 of LRP5. The wild-type or truncated LRP5 mRNAs were detected by primary PCR for most of the tumors or with nested PCR using an additional overlapping forward primer. The truncation comprised the last 93 bp of exon 9, all 227 bp of exon 10, and the first 106 bp of exon 11.
###end p 47
###begin p 48
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
(B) Nested RT-PCR of normal parathyroid tissue (n = 6), and parathyroid tumor cell line sHPT-1 [8] as marker (top panel). Nested RT-PCR analysis of 17 normal tissues, and the parathyroid tumor pHPT21 as marker (lower panel).
###end p 48
###begin p 49
###xml 197 198 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 162 167 <span type="species:ncbi:9606">human</span>
(C) Immunoprecipitation followed by Western blot analysis of LRP5. Transiently expressed (HEK293T cells) LRP5 and LRP5Delta666-809 shown as size markers. sHPT-1, human parathyroid tumor cell line [8]; pHPT, pHPT tumor. The lower panel shows additional pHPT tumor samples analyzed on a 5% SDS-polyacrylamide gel, where the proteins separate more clearly.
###end p 49
###begin p 50
(D) A schematic structure of LRP5 is shown. The truncated mRNA contains an in-frame deletion of LRP5 between amino acids 666 and 809 (Delta666-809), encompassing the third YWTD beta-propeller domain. The truncation (Delta666-809) is flanked by imperfect direct repeat sequences (horizontal arrows) with putative cryptic donor (Ac-GTG) and acceptor (AC-cT) RNA splice sites in exons 9 and 11, respectively (arrows). The Delta666-809 is between nucleotide positions 2039 and 2466 of the LRP5 mRNA (GenBank accession no. AF064548).
###end p 50
###begin title 51
Specificity and Efficiency of siRNAs Transiently Transfected to the sHPT-1 Parathyroid Tumor Cell Line
###end title 51
###begin p 52
(A) Locations of siRNAs and probes for quantitative real-time PCR. tot mRNA PCR probe determines both LRP5wt and LRP5Delta666-809 transcripts.
###end p 52
###begin p 53
(B) Expression of LRP5wt and LRP5tot mRNA assessed by quantitative real-time PCR. (C) Immunoprecipitation and Western blot analysis of LRP5.
###end p 53
###begin p 54
###xml 174 176 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b028">28</xref>
###xml 177 179 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b029">29</xref>
###xml 251 259 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 439 447 424 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 620 622 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b030">30</xref>
The tumor-associated shorter transcript LRP5Delta666-809 contained an in-frame deletion of 142 amino acids (Delta666-809), encompassing the third YWTD beta-propeller domain [28,29] between the second and third epidermal growth factor repeats of LRP5 (Figure 1D). The deletion (Delta666-809) was flanked by imperfect direct repeat sequences with putative cryptic donor and acceptor RNA splice sites located in exons 9 and 11, respectively (Figure 1D). The 5' putative cryptic splice site (Ac-GTG) related to the consensus sequence of major-class introns and the 3' cryptic splice (AC-cT) related more to the minor-class [30]. The genomic sequences of exon/intron junctions and branch points in question as well as exons 10 and 11 did not reveal any abnormalities in several tumors. Also, no deletion was noted by Southern blotting of genomic DNA (unpublished data). The LRP5 internal truncation is most likely the result of cryptic splice site usage.
###end p 54
###begin title 55
The Internally Truncated LRP5 Receptor Contributes to Active beta-Catenin Signaling
###end title 55
###begin p 56
###xml 141 142 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 273 281 269 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g002">Figure 2</xref>
###xml 566 574 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 759 768 743 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figures 1</xref>
###xml 774 775 758 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g002">2</xref>
###xml 976 984 960 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g002">Figure 2</xref>
###xml 990 991 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g002">2</xref>
###xml 179 184 <span type="species:ncbi:9606">human</span>
To investigate the functional consequences of LRP5Delta666-809 expression, if any, specific and control siRNAs were efficiently transfected [8] to the recently established unique human parathyroid tumor cell line sHPT-1. Three different siRNAs against LRP5 mRNA were used (Figure 2A): one against the LRP5wt transcript (siLRP5wt), one against the internally truncated transcript (siLRP5Delta666-809), and one recognizing both the LRP5wt and LRP5Delta666-809 transcripts (siRNAtot). siLRP5wt was directed to exon 10, which was excluded from the truncated transcript (Figure 1A); siLRP5Delta666-809 was directed against the unique sequence created at the aberrant exon junction; and siRNAtot was directed to exon 13, which was present in both LRP5 transcripts (Figures 1D and 2A). A nonsilencing siRNA (control siRNA) and a mutant siRNAtot (control siRNAtot) were also used. Specificity and silencing potential of the siRNAs were ascertained both at the mRNA and protein level (Figure 2B and 2C).
###end p 56
###begin p 57
###xml 268 276 258 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">Figure 3</xref>
###xml 282 283 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">3</xref>
###xml 487 495 470 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">Figure 3</xref>
###xml 501 502 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">3</xref>
###xml 594 602 577 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g001">Figure 1</xref>
###xml 647 655 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">Figure 3</xref>
###xml 700 701 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 890 898 869 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g003">Figure 3</xref>
###xml 1141 1149 1110 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 1285 1288 1247 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1290 1292 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b022">22</xref>
###xml 1350 1351 1312 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 1361 1364 1323 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1542 1550 1500 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 1568 1571 1526 1529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 1641 1642 1596 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 1836 1839 1788 1791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 2011 2019 1960 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 2154 2162 2096 2104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 2198 2201 2140 2143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 2219 2227 2161 2169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 2288 2291 2227 2230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 2323 2331 2262 2270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
Transfection of siLRP5Delta666-809 reduced the nonphosphorylated active beta-catenin level markedly as well as decreased the growth of sHPT-1 cells. siLRP5wt showed a tendency toward a lowered beta-catenin level, but no significant effect on cell growth was observed (Figure 3A and 3B). In agreement with these results, transfection of siRNA specific for both LRP5 transcripts (siLRP5tot) resulted in similar diminished beta-catenin expression and cell growth as for siLRP5Delta666-809 (Figure 3A and 3B). The growth of HeLa cells, which did not express the internally truncated LRP5 receptor (Figure 1C), was not affected by siRNA transfections (Figure 3B). As shown previously for siRNA to CTNNB1 [8], sHPT-1 cells transfected with siLRP5Delta666-809 but not with control siRNA showed accumulation of dead cells as well as a smaller population of apoptotic cells 84 h after transfection (Figure 3C). Furthermore, the endogenous beta-catenin activity in sHPT-1 cells (11-fold), as measured by FOPFLASH/TOPFLASH TCF/beta-catenin luciferase reporter transfection, was dependent on maintained expression of LRP5Delta666-809 and not of LRP5wt (Figure 4A). Dependence on maintained expression of LRP5Delta666-809 was also observed for expression of the endogenous beta-catenin target gene MYC [22], which is commonly overexpressed in parathyroid tumors [5], as the MYC mRNA level was significantly reduced in sHPT-1 parathyroid cells transfected with siLRP5Delta666-809 and siLRP5tot, but not with siLRP5wt, control siRNA, and control siLRP5tot (Figure 4A). Expression of MYC in sHPT-1 cells has been shown previously to depend on beta-catenin [8]. Thus, maintained expression of the internally truncated LRP5 receptor in sHPT-1 cells appeared necessary for accumulation of transcriptionally active beta-catenin, continued cell growth, and MYC expression. An effect of the internally truncated LRP5 receptor on beta-catenin signaling was further substantiated by experiments in HEK293T cells. Transient expression (Figure 4B) of LRP5Delta666-809 and not of LRP5wt in these cells resulted in increased level (5-fold) of nonphosphorylated active beta-catenin (Figure 4C), a 5-fold increase of endogenous MYC mRNA expression (Figure 4D), and enhanced association (4-fold) of beta-catenin to the MYC promoter, as revealed by ChIP (Figure 4E).
###end p 57
###begin title 58
Maintained Expression of the Internally Truncated LRP5 Receptor Is Required for Accumulation of Nonphosphorylated beta-Catenin and Continued Cell Growth
###end title 58
###begin p 59
###xml 50 52 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b025">25</xref>
(A) Western blot analysis of active beta-catenin [25], 60 h after transfection. The beta-catenin-actin signal ratio is shown.
###end p 59
###begin p 60
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(B) Effects on sHPT-1 cell growth. HeLa cells were used as control for toxic effects. *p < 0.05.
###end p 60
###begin p 61
(C) Flow cytometry analysis of sHPT-1 cells at 84 h after transfection after staining with annexin V-FITC and propidium iodide. Accumulation of dead cells in the upper left quadrant; population of late apoptotic cells (upper right quadrant) and early apoptotic cells (lower right quadrant).
###end p 61
###begin title 62
The Internally Truncated LRP5 Receptor Regulates beta-Catenin-Driven Transcription
###end title 62
###begin p 63
###xml 247 249 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b022">22</xref>
###xml 346 349 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 393 394 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 86 89 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) Transient cotransfections of FOPFLASH or TOPFLASH TCF/beta-catenin reporters, the CMV-LacZ reference plasmid, and indicated siRNAs to sHPT-1 cells (left panel). FOPFLASH contains mutated binding sites for TCF factors, while TOPFLASH does not [22]. Luciferase activities were normalized to beta-galactosidase activities. Effects on endogenous MYC expression in sHPT-1 cells (right panel). *p < 0.05.
###end p 63
###begin p 64
(B) Western blot analysis of V5-tagged LRP5 and LRP5Delta666-809 transiently transfected to HEK293T cells. LRP5 and LRP5Delta666-809 were expressed at similar levels.
###end p 64
###begin p 65
(C) Western blot analysis of cytosolic nonphosphorylated active beta-catenin in HEK293T cells, 24 h after transfection.
###end p 65
###begin p 66
###xml 15 18 15 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(D) Endogenous MYC expression in transfected HEK293T cells. *p < 0.05.
###end p 66
###begin p 67
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 117 119 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b025">25</xref>
(E) ChIP of the MYC promoter in transfected HEK293T cells. An anti-active-beta-catenin monoclonal antibody was used [25].
###end p 67
###begin title 68
WNT3 Ligand and the Internally Truncated LRP5 Receptor Strongly Activate Transcription with Impaired DKK1 Inhibition
###end title 68
###begin p 69
###xml 554 562 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
###xml 755 759 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WNT3</italic>
###xml 768 772 751 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WNT1</italic>
###xml 820 828 803 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
The effects of WNT ligand stimulation of the LRP5wt and LRP5Delta666-809 receptors were determined by transient cotransfection of the TOPFLASH TCF/beta-catenin luciferase reporter and the LRP5 receptor expression vectors to sHPT-1 cells, followed by incubation in WNT1, WNT3, or WNT3A conditioned medium. Transfected LRP5Delta666-809 displayed activation of beta-catenin driven transcription in sHPT-1 cells (9-fold), and transcription was most prominently stimulated (80-fold) in the presence of WNT3 ligand, where it was 4-fold higher than for LRP5wt (Figure 5A). In addition, only WNT3 stimulated the endogenous beta-catenin activity (9-fold). WNT3A ligand stimulated transcription only in the presence of LRP5wt (10-fold), and WNT1 showed no effects. WNT3 but not WNT1 was expressed by RT-PCR in parathyroid tumors (Figure 5B).
###end p 69
###begin title 70
WNT3 Ligand and the Internally Truncated LRP5 Receptor Strongly Activates Transcription of the TOPFLASH TCF/beta-Catenin Luciferase Reporter with Impaired DKK1 Inhibition
###end title 70
###begin p 71
###xml 313 321 309 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g004">Figure 4</xref>
###xml 97 100 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) sHPT-1 cells cotransfected with TOPFLASH, LRP5wt, or LRP5Delta666-809 expression vectors and CMV-LacZ reference plasmid, followed by incubation in WNT1, WNT3, or WNT3A conditioned medium (CM). CM was from HEK293T cells transfected transiently with expression vectors for the various WNT ligands. The 11-fold (Figure 4A) endogenous beta-catenin activity is set to 1 (unstimulated, empty vector).
###end p 71
###begin p 72
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b021">21</xref>
(B) Representative RT-PCR analysis of RNA from three pHPT and three sHPT tumors using primers for WNT3. No expression of WNT1 was detected by the conditions used [21].
###end p 72
###begin p 73
###xml 35 38 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(C) Cotransfection of TOPFLASH and CMV-LacZ reference plasmid to sHPT-1 cells. Incubation in WNT3 and DKK1 CM.
###end p 73
###begin p 74
###xml 32 35 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(D) Cotransfection of TOPFLASH, CMV-LacZ reference plasmid, and LRP5wt or LRP5Delta666-809 expression vectors to HEK293T cells followed by incubation in WNT1, WNT3, or DKK1 CM. HEK293T cells do not express the internally truncated LRP5 receptor.
###end p 74
###begin p 75
###xml 165 167 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b031">31</xref>
###xml 454 462 444 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
###xml 491 499 481 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
###xml 668 676 654 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
###xml 803 811 785 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
###xml 1041 1049 1019 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g005">Figure 5</xref>
Several amino acid residues in the deleted part of LRP5 (Delta666-809) were shown to be required for inhibition of beta-catenin activity by the WNT antagonist DKK1 [31]. Therefore, we examined the effect of DKK1, which is expressed in parathyroid tumors (unpublished data) on WNT3-stimulated beta-catenin activity in sHPT-1 cells. The presence of DKK1 in the culture medium resulted in inhibition of WNT3 activation in HEK293T control cells as expected (Figure 5D), but not in sHPT-1 cells (Figure 5C). In agreement with these results, WNT3-induced TOPFLASH transcription was inhibited by DKK1 in HEK293T cells cotransfected with LRP5wt and not with LRP5Delta666-809 (Figure 5D). Also, the activity of LRP5Delta666-809 in unstimulated cells (7-fold) was insensible to DKK1. In contrast to sHPT-1 cells (Figure 5A), HEK293T cells responded to WNT1-conditioned medium (7-fold) and was sensitive to DKK1 inhibition as expected. However, the small increase of LRP5Delta666-809 activity in the presence of WNT1 (1.7-fold) was insensible to DKK1 (Figure 5D). The impaired DKK1-mediated antagonism of beta-catenin activity may contribute to overall signaling of the internally truncated LRP5 receptor.
###end p 75
###begin title 76
###xml 35 39 <span type="species:ncbi:10090">Mice</span>
Inhibition of Tumor Growth in SCID Mice
###end title 76
###begin p 77
###xml 265 273 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g006">Figure 6</xref>
###xml 279 280 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040328-g006">6</xref>
###xml 468 469 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b008">8</xref>
###xml 536 538 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b032">32</xref>
###xml 81 86 <span type="species:ncbi:10090">mouse</span>
The in vivo growth properties of sHPT-1 cells were evaluated in a xenograft SCID mouse model. Significant tumor growth inhibition was observed in transplants of cells when pretransfected with siLRP5Delta666-809 or siLRP5tot, but not with siLRP5wt or control siRNA (Figure 6A and 6B). Thus, the internally truncated LRP5 receptor appeared to be required for tumor growth in this animal model. Combination of the very high siRNA transfection efficiency of sHPT-1 cells [8] and generally prolonged gene silencing in slowly dividing cells [32] are likely prerequisites for the sustained tumor growth inhibition observed 8-9 wk after transplantation.
###end p 77
###begin title 78
###xml 90 94 <span type="species:ncbi:10090">Mice</span>
siRNAs to the Internally Truncated LRP5 Receptor Inhibit Tumor Growth in Xenografted SCID Mice
###end title 78
###begin p 79
(A) Injection of sHPT-1 cells pretransfected for 24 h with siLRP5Delta666-809 or control siRNA. Arrows indicate representative parathyroid tumor growth at site of transplantation.
###end p 79
###begin p 80
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 151 152 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
(B) Parathyroid tumors from SCID mice (n = 35) injected with sHPT-1 cells pretransfected for 24 h with the indicated siRNAs were excised and weighed. *p < 0.05. The animals were monitored every day and killed after 8-9 wk.
###end p 80
###begin title 81
Discussion
###end title 81
###begin p 82
###xml 175 176 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 329 335 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 514 515 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b005">5</xref>
###xml 657 663 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 697 699 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b033">33</xref>
###xml 769 771 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b034">34</xref>
###xml 850 856 844 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 892 894 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b035">35</xref>
###xml 1017 1023 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 1350 1352 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b013">13</xref>
###xml 1353 1355 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b014">14</xref>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 759 767 <span type="species:ncbi:9606">patients</span>
###xml 978 986 <span type="species:ncbi:9606">patients</span>
beta-catenin accumulation has been observed by us in all so far analyzed parathyroid tumors of primary origin and hyperplastic parathyroid glands of HPT secondary to uremia ([5] and this work), strongly suggesting dysregulated WNT/beta-catenin signaling as a common pathogenic pathway for these different conditions. We reported CTNNB1-stabilizing mutations in a few cases (3 out of 20) of pHPT tumors, while no mutation was found in uremic secondary HPT tumors, and inactivating truncations of APC were not seen [5]. Recently, parathyroid adenomas from 97 patients with pHPT who had undergone parathyroidectomy in the United States were analyzed regarding CTNNB1-stabilizing mutations in exon 3 [33]. In agreement with one previous smaller study of Japanese patients [34], no mutations were identified. Taken together, these results indicated a low CTNNB1 mutation frequency in pHPT tumors [35]. We are currently analyzing a large number of additional pHPT tumors from Swedish patients. A few additional tumors with CTNNB1-stabilizing mutations has been found so far, suggesting an overall mutation frequency of approximately 6% (Bjorklund et al., unpublished data). This frequency is slightly lower than that observed for colorectal cancers, in which approximately 10% of the tumors harbored missense mutations or interstitial deletions of exon 3 [13,14].
###end p 82
###begin p 83
###xml 506 512 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 552 558 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 687 693 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
Several lines of experimental evidence presented here support a fundamental role of the internally truncated LRP5 receptor in regulating beta-catenin-driven transcription in parathyroid tumor cells. The truncated LRP5 receptor was frequently expressed both in parathyroid tumors of primary origin (86%) and in hyperplastic parathyroid glands of HPT secondary to uremia (100%). Of all 57 analyzed parathyroid tumors with accumulated beta-catenin, 52 expressed the internally truncated LRP5 receptor without CTNNB1-stabilizing mutations, four tumors had CTNNB1-stabilizing mutations but no truncated LRP5 receptor, and 1 tumor displayed neither aberration. Thus, it seems that mutation of CTNNB1 and expression of LRP5Delta666-809 is mutually exclusive.
###end p 83
###begin p 84
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 308 312 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 463 465 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b036">36</xref>
###xml 637 639 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b037">37</xref>
All reported LRP5 missense mutations, which cause a high-bone-mass phenotype, are located before the first epidermal growth factor-like repeat in the amino terminal part of the receptor, not including the third YWTD beta-propeller domain, which is absent in the truncated LRP5 receptor. Several mutations of LRP5 known to cause osteoporosis-pseudoglioma syndrome is located within amino acids 666-809, highlighting a functional role for this part of the protein [36]. Osteoporosis-pseudoglioma mutations seem to cause varying degree of reduced Wnt or Norrin signaling by unknown mechanisms, as determined by the TOPFLASH reporter assay [37]. Clearly, the deletion of 142 amino acids in LRP5Delta666-809 and a missense mutation in the same part of the receptor have opposite effects. A missense mutation may for example interfere with binding of cell-type-specific factor(s), while a larger deletion may result in structural changes of the receptor with a different impact on cofactor interactions and signal outcome. The mechanism(s) by which the internally truncated LRP5 receptor activates beta-catenin signaling in tumor cells remains to be elucidated, but may involve impaired inhibition by DKK1. The WNT3 ligand activated transient transcription more strongly in the presence of LRP5Delta666-809 than LRP5wt, possibly suggesting favored interaction of WNT3 with the internally truncated receptor. We emphasize that the conditioned medium of WNT1, WNT3, WNT3A, and DKK1 used throughout this study might contain uncharacterized signaling molecules induced by the WNTs or DKK1.
###end p 84
###begin p 85
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b038">38</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b039">39</xref>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MDM2</italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b040">40</xref>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LRP5</italic>
###xml 763 768 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040328-b041">41</xref>
RNA splicing defects in cancer are common, but seem rarely to be caused by somatic mutations in splice sites and regulatory elements. Alternative splicing may potentially present as a diagnostic marker [38,39]. Interestingly, aberrant splicing between direct repeat sequences with potential cryptic splice sites and without mutations in selected parts of the gene has been described also for the MDM2 oncogene in breast cancer [40]. We found no mutations or polymorphisms in the sequenced exons/branch points/intron-exon junctions of the LRP5 gene in the analyzed tumors that potentially could explain the aberrant splicing. Mutations in other areas of the LRP5 gene affecting splicing specificity, accuracy, or efficiency, or perhaps more likely interference of trans-acting factors of the splicing machinery, are other possibilities. Alternative splicing may be affected in a splicing factor concentration-dependent manner [41], and this may also apply to aberrant splicing in tumors. Identification of splicing oncogenes or splicing tumor suppressor genes is being pursued.
###end p 85
###begin p 86
The results support a fundamental role of the aberrantly spliced internally truncated LRP5 receptor in activating WNT/beta-catenin signaling in parathyroid tumor cells. LRP5 receptors could be attractive targets for the development of antitumor drugs that specifically inactivate the truncated receptor and leave the normal protein unaffected.
###end p 86
###begin p 87
We are grateful to B. Bondeson and P. Lillhager for skillful and extensive technical assistance. We thank Drs. R. Kemler, J. Kitajewski, S. Sokol, and B. Williams for providing expression plasmids.
###end p 87
###begin title 88
Abbreviations
###end title 88
###begin p 89
adenomatosis polyposis coli
###end p 89
###begin p 90
chromatin immunoprecipitation
###end p 90
###begin p 91
hyperparathyroidism
###end p 91
###begin p 92
low-density lipoprotein receptor-related protein 5
###end p 92
###begin p 93
primary hyperparathyroidism
###end p 93
###begin p 94
severe combined immunodeficiency
###end p 94
###begin p 95
secondary hyperparathyroidism
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
Hyperparathyroid and hypoparathyroid disorders
###end article-title 97
###begin article-title 98
Molecular pathogenesis of primary hyperparathyroidism
###end article-title 98
###begin article-title 99
Primary hyperparathyroidism
###end article-title 99
###begin article-title 100
###xml 45 50 <span type="species:ncbi:9606">human</span>
Parathyroid glands in calcium regulation and human disease
###end article-title 100
###begin article-title 101
Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors
###end article-title 101
###begin article-title 102
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells
###end article-title 102
###begin article-title 103
Myc deletion rescues Apc deficiency in the small intestine
###end article-title 103
###begin article-title 104
###xml 36 41 <span type="species:ncbi:9606">human</span>
Activated beta-catenin in the novel human parathyroid tumor cell line sHPT-1
###end article-title 104
###begin article-title 105
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice
###end article-title 105
###begin article-title 106
A novel cyclin encoded by a bcl1-linked candidate oncogene
###end article-title 106
###begin article-title 107
Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine
###end article-title 107
###begin article-title 108
The oncogenic activation of beta-catenin
###end article-title 108
###begin article-title 109
The Wnt signaling pathway and its role in tumor development
###end article-title 109
###begin article-title 110
Caught up in a Wnt storm: Wnt signaling in cancer
###end article-title 110
###begin article-title 111
WNT and beta-catenin signalling: diseases and therapies
###end article-title 111
###begin article-title 112
LDL-receptor-related proteins in Wnt signal transduction
###end article-title 112
###begin article-title 113
###xml 59 63 <span type="species:ncbi:10090">mice</span>
An LDL-receptor-related protein mediates Wnt signalling in mice
###end article-title 113
###begin article-title 114
Arrow encodes an LDL-receptor-related protein essential for Wingless signalling
###end article-title 114
###begin article-title 115
Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex
###end article-title 115
###begin article-title 116
Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway
###end article-title 116
###begin article-title 117
Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation
###end article-title 117
###begin article-title 118
Identification of c-MYC as a target of the APC pathway
###end article-title 118
###begin article-title 119
Downstream promoter sequences facilitate the formation of a specific transcription factor IID-promoter complex topology required for efficient transcription from the megalin/low density lipoprotein receptor-related protein 2 promoter
###end article-title 119
###begin article-title 120
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation
###end article-title 120
###begin article-title 121
Wnt signaling controls the phosphorylation status of beta-catenin
###end article-title 121
###begin article-title 122
Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase
###end article-title 122
###begin article-title 123
UKCCCR guidelines for the welfare of animals in experimental neoplasia
###end article-title 123
###begin article-title 124
Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair
###end article-title 124
###begin article-title 125
Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface
###end article-title 125
###begin article-title 126
Splicing double: Insights from the second spliceosome
###end article-title 126
###begin article-title 127
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd
###end article-title 127
###begin article-title 128
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
###end article-title 128
###begin article-title 129
Absence of stabilizing mutations of beta-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas
###end article-title 129
###begin article-title 130
Immunohistochemistry of cyclin D1 and beta-catenin, and mutational analysis of exon 3 of beta-catenin gene in parathyroid tumors
###end article-title 130
###begin article-title 131
Ruling out a suspect: the role of beta-catenin mutation in benign parathyroid neoplasia
###end article-title 131
###begin article-title 132
LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders
###end article-title 132
###begin article-title 133
Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome
###end article-title 133
###begin article-title 134
###xml 99 104 <span type="species:ncbi:9606">human</span>
Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer
###end article-title 134
###begin article-title 135
Alterations of pre-mRNA splicing in cancer
###end article-title 135
###begin article-title 136
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdm2</italic>
Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer
###end article-title 136
###begin article-title 137
The gene encoding the splicing factor SF2/ASF is a proto-oncogene
###end article-title 137
###begin p 138
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. GW designed the study. PB performed experiments and analyzed data. PB, GA, and GW interpreted the data. GA reviewed clinical data. PB, GA, and GW contributed to writing the paper.
###end p 138
###begin p 139
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
###xml 94 99 <span type="species:ncbi:9689">Lions</span>
Funding: This work was supported by the Swedish Research Council, Swedish Cancer Society, and Lions Fund for Cancer Research. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript.
###end p 139
###begin p 140
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors declare the following competing interest: A patent is filed (USA) for "LRP5 and LRP6 Receptors in Cancer Treatment," number WO2005048913.
###end p 140

